Gilead Hopes To Dodge New Trial With Cystic Fibrosis Antibiotic
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Complete response letter for Cayston (aztreonam) requests another study, but Gilead is talking with FDA to see if re-analysis of existing data will suffice
You may also be interested in...
Gilead’s Cystic Fibrosis Drug Looks Good Long-Term, Firm Reports
Convenience and tolerability benefits could position aztreonam lysine as best-in-class.
Another Hybrid License Deal: Chiesi Buys Majority Stake In Cornerstone
In a creative deal that echoes the strategic tie-up last year between Infinity and Mundipharma, Italian giant Chiesi Farmaceutici is buying a majority stake in Cornerstone Therapeutics, which gets $15.5 million along with U.S. rights for 10 years to Chiesi's marketed lung surfactant Curosurf
Another Hybrid License Deal: Chiesi Buys Majority Stake In Cornerstone
With a would-be competitor from Discovery Labs stalled at FDA, approved lung surfactant Curosurf sits at the center of equity, cash tie-up.